PHYSICIAN REPORTED TREATMENT ATTRIBUTES CONSIDERED IN FIRST-LINE AND PERCEPTIONS AROUND BRUTON TYROSINE KINASE INHIBITOR (BTKI) TREATMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) IN THE US

被引：0
|
作者：
Jensen, C. [1 ]
Ding, Z. [2 ]
Greenwood, T. [3 ]
Kluth, C. [3 ]
Sanderson, I [3 ]
Milloy, N. [3 ]
Mavani, H. [2 ]
Khan, W. [2 ]
Qureshi, Z. P. [2 ]
机构：
[1] Univ N Carolina, Div Hematol, Chapel Hill, NC USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Adelphi Real World, Bollington, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO102
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [21] Fixed-duration orelabrutinib plus bendamustine and rituximab versus continuous Bruton Tyrosine Kinase inhibitor (BTKi) in treatment-naive chronic/small lymphocytic leukemia (CLL/SLL): A multicenter, nonrandomized, pragmatic clinical trial
    Cao, L-L.
    Ding, K-Y.
    Song, H.
    Wang, C-C.
    Xu, Q.
    Zhou, C-Y.
    Hu, M-G.
    Ming, J.
    Wu, G-L.
    Fan, D-D.
    Feng, Y-Y.
    Wang, X-C.
    ANNALS OF ONCOLOGY, 2024, 35 : S612 - S612
  • [22] Understanding Patient and Physician Perceptions Regarding Treatment-Related Adverse Events in First-Line Chronic Lymphocytic Leukemia (CLL)
    Sile, Bersabeh
    Horchi, Dahbia
    Rault, Bleuenn
    Mulvihill, Emily
    Beusterien, Kathleen
    Stewart, Katherine
    De Miranda, Paulo Andre P. Palhares
    Guillaume, Xavier
    BLOOD, 2023, 142
  • [23] BRUTON TYROSINE KINASE INHIBITOR (BTKI) MONOTHERAPY FOR THE TREATMENT OF 'HIGH-RISK' PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Mohseninejad, L.
    Walder, L.
    Ubi, S.
    Malyon, A.
    Yang, K.
    Olie, R.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [24] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
    Tam, Constantine S.
    Siddiqi, Tanya
    Allan, John N.
    Kipps, Thomas J.
    Flinn, Ian W.
    Kuss, Bryone J.
    Opat, Stephen
    Barr, Paul M.
    Tedeschi, Alessandra
    Jacobs, Ryan
    Badoux, Xavier C.
    Ghia, Paolo
    Sukbuntherng, Juthamas
    Salem, Ahmed Hamed
    Russell, Kristin
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    James, Danelle F.
    Wierda, William G.
    BLOOD, 2019, 134
  • [25] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Salkar, Monika
    Saifan, Chadi
    Agatep, Barnabie C.
    Jones, Barton
    Ryan, Olga
    Bacchus, Shaffee
    Stephens, Deborah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    BLOOD, 2018, 132
  • [27] Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL ( CSCLL)
    Mihalyova, Jana
    Panovska, Anna
    Simkovic, Martin
    Turcsanyi, Peter
    Spacek, Martin
    Brejcha, Martin
    Lysak, Daniel
    Mocikova, Heidi
    Pavlova, Sarka
    Chrapava, Marika
    Zuchnicka, Jana
    Brychtova, Yvona
    Vodarek, Pavel
    Urbanova, Renata
    Likarova, Tereza
    Malcikova, Jitka
    Jurkova, Tereza
    Lancova, Klara
    Bezdekova, Lucie
    Papajik, Tomas
    Baranova, Jana
    Arpas, Tomas
    Pospisilova, Sarka
    Smolej, Lukas
    Doubek, Michael
    BLOOD, 2023, 142
  • [28] Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting
    Burke, John M.
    Zackon, Ira
    Wayne, Brittani
    Wang, Yunfei
    Murphy, John
    Prescott, Jennifer
    Gandra, Shravanthi
    Leng, Siyang
    De Nigris, Enrico
    BLOOD, 2024, 144 : 7811 - 7812
  • [29] COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)-A two-cohort phase II study.
    Wendtner, Clemens-Martin
    Byrd, John C.
    Foa, Robin
    Greil, Richard
    Hillmen, Peter
    Jager, Ulrich
    Jurczak, Wojciech
    Kelemen, Peter
    Laribi, Kamel
    Munir, Talha
    Schetelig, Johannes
    Staber, Philipp B.
    Stilgenbauer, Stephan
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients
    Lin, Kevin H.
    Huynh, Lynn
    Yang, Xiaoqin
    Zanardo, Enrico
    Lema, Neema
    Matay, Lisa
    Balasubramanian, Sobana
    Liborski, Daria
    McDonough, Mikaela
    Foreman, Jillian
    Farooqui, Mohammed Z. H.
    De Nigris, Enrico
    Gandra, Shravanthi R.
    Sarpong, Eric M.
    Duh, Mei Sheng
    Brown, Jennifer R.
    Davids, Matthew Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345